Abstract 63P
Background
Breast cancer is one of the cancers with highest incidence with more than two million people diagnosed in 2018 and causes more than 600.000 deaths. The big number of deaths are mostly due to breast cancer metastasis. Butterfly pea flower (Clitoria ternatea Linn.) is a medicinal plant which is known to have a wide range of pharmacological activities because it contains many kinds of active substances one of which is quercetin known to have anti-breast cancer activity especially metastasis through inhibition of NF-κB (nuclear factor kappa B). Those transcription factors play an important role in the metastasis process in HER2-positive breast cancer type. The butterfly pea flower activity as an antimetastatic agent in MCF-7 HER2-positive has not been well understood. The aim of the study was to find out the antimetastatic activity of butterfly pea flower extract on MCF-7 HER-positive breast cancer cell line.
Methods
Maceration process using 96% ethanol to obtain the crude extract, thin layer chromatography (TLC) to see the phytochemical profile of butterfly pea leaf extract, MTT assay to determine the IC50 using log probit analysis as a reference for the next test which is scratch wound healing assay to assess the effect of butterfly pea leaf extract on the migration of 4T1 breast cancer cell line.
Results
Butterfly pea flower extraction using maceration obtains a 18.06% yield. Phytochemical study using thin layer chromatography suggested the Rf of crude extract had the same Rf with quercetin standard which is 0.57 so it was proven that the crude extract contained quercetin. The MTT assay and log probit analysis showed the IC50 of butterfly pea crude extract was 862 μg/mL. The scratch wound healing assay using concentrations below IC50 showed 50% of cell migration activity of the MCF-7 HER2-positive was inhibited in 24 hours interval by 380 μg/mL crude extract and in 48 hours interval with 500 μg/mL of crude extract was able to prevent the scratch closure. Statistical analysis using SPSS 16.0 showed that the crude extract can significantly suppressed the migration of the cancer cell.
Conclusions
Butterfly pea flower extract has an antimetastatic activity to MCF-7 HER2-positive breast cancer cell line in-vitro.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
UGM.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
360P - Number of lymph nodes examined was not an independent risk factor for the survival of patients with stage IA1-2 lung adenocarcinoma undergoing sublobar resection
Presenter: Zhenbin Qiu
Session: e-Poster Display Session
361P - Radiomic model predicting radiological response after thoracic stereotactic body radiotherapy regardless of tumor histology and staging
Presenter: Ben Man Fei Cheung
Session: e-Poster Display Session
362P - Integrative and comparative genomic analysis and immune microenvironment features of lung cancer patients with tuberculosis
Presenter: Xiaoling Xu
Session: e-Poster Display Session
363P - Genetic predisposition for pre-invasive lung adenocarcinoma manifesting as ground-glass nodules with family history of lung cancer
Presenter: Rui Fu
Session: e-Poster Display Session
364P - A deep learning model for the classification of lung cancer
Presenter: Gouji Toyokawa
Session: e-Poster Display Session
365P - Utilization of on-site pathology evaluation for lung cancer diagnosis in the Philippines’ National University Hospital
Presenter: Rich Ericson King
Session: e-Poster Display Session
367P - Detection of epidermal growth factor receptor mutations (EGFR-mut) from cell-free DNA in pleural effusion (PE-DNA) of patients with non-small cell lung cancer (NSCLC)
Presenter: Kirsty Lee
Session: e-Poster Display Session
368P - Real-world characteristics, treatment, and outcomes of stage III non-small cell lung cancer in Japan: SOLUTION study
Presenter: Haruyasu Murakami
Session: e-Poster Display Session
369P - The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
Presenter: Long Jiang
Session: e-Poster Display Session
371P - Real-world insights into treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): KINDLE study India analysis
Presenter: Kumar Prabhash
Session: e-Poster Display Session